How Did Evolent Health (NYSE:EVH) Revenue Rise 51% While Adjusted EBITDA Fell?

Sonal Goyal

06 November 2026 04:14 PM AEDT

How Did Evolent Health (NYSE:EVH) Revenue Rise 51% While Adjusted EBITDA Fell?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue rose to $725.4 million from $479.5 million in the third quarter.
Adjusted EBITDA was $34.3 million, compared with $39.0 million a year earlier.
The net loss attributable to common shareholders narrowed to $23.6 million.
The adjusted EBITDA Margin fell to 4.7% from 8.1%.

Evolent Health, Inc. (NYSE:EVH), a company focused on better health outcomes for people with complex conditions, reported third-quarter 2026 results for the three months ended September 30, 2026. Revenue rose to $725.4 million from $479.5 million, while adjusted EBITDA declined to $34.3 million. The net loss attributable to common shareholders narrowed. Chief executive Seth Blackley said health plan customers continued to renew and expand their agreements with the company.

Revenue Growth and Customer Demand

Third-quarter revenue of $725.4 million was up sharply from $479.5 million in the prior-year quarter. The company attributed continued Demand to health plan customers that renewed their agreements and in many cases expanded the work they do with Evolent, a pattern that adds to the company's revenue base over time.

Blackley also pointed to the company's 2026 oncology launches as a source of execution in the period. New product launches in a specialty area can add revenue quickly once they reach clients, although the release does not quantify the contribution of oncology to the quarter.

Net Loss and Margin

The net loss attributable to common shareholders was $23.6 million, compared with $26.9 million a year earlier. The net loss margin improved to negative 3.2% from negative 5.6%, which means the company lost a smaller share of each revenue dollar than it did last year.

The narrower loss came even as revenue rose sharply, which indicates that the company's cost of services grew more slowly than sales. Readers can see the drivers of the improvement in the company's income statement, which the release presents alongside the summary figures.

Adjusted EBITDA and Margin Compression

Adjusted EBITDA fell to $34.3 million from $39.0 million, and the adjusted EBITDA margin declined to 4.7% from 8.1%. The fall in adjusted EBITDA alongside a sharp revenue increase suggests that the company's operating costs and mix shifted in a way that reduced profitability per dollar of revenue.

Margin compression on a larger revenue base can reflect lower-margin contracts, startup costs for new programs or the pass-through of certain costs. The release does not provide a full explanation, so investors should look for the company's commentary on margins in the full Earnings materials.

Platform Metrics and Cases

The release reports average lives on platform and cases across the company's suites. Platform metrics provide a view of the Volume of members and cases the company manages, which feeds into revenue for its services.

The company's case count and member figures help readers judge whether revenue growth reflects more volume or higher revenue per case. The release's tables show each metric separately, which allows that comparison across the two periods.

Outlook

Evolent Health's third-quarter report pairs a 51% revenue increase with a narrower net loss and a lower adjusted EBITDA margin. The company's ability to restore margins while growing revenue through client renewals and oncology launches will determine how its profitability develops in future quarters.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.